Legend Biotech Corporation
NASDAQ · LEGN·Somerset, NJ·Large-cap·Approved
Cell therapy company with Carvykti (ciltacabtagene autoleucel), a BCMA-targeted CAR-T therapy partnered with Johnson & Johnson for relapsed/refractory multiple myeloma. Legend's pipeline includes next-generation CAR-T programs across hematologic and solid tumor indications.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Legend Biotech Q3 2025 Corporate Update | Earnings | November 12, 2025 | 27 |